For thousands of women navigating the journey of breast cancer treatment, the road to recovery often includes breast reconstruction. A gold-standard approach in this process involves the use of tissue expanders—devices placed under the skin to gradually stretch the tissue in preparation for a permanent implant. While this procedure is routine, it carries a significant, persistent challenge: surgical site infections (SSIs).
A groundbreaking study published in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), has uncovered a counterintuitive risk factor for these infections: the recent use of antibiotics. According to the research, patients who took antibiotics within 30 days prior to their tissue expander surgery faced a four-fold increase in the risk of developing a surgical site infection.
The Core Findings: A Paradoxical Discovery
The study, conducted by a team led by Bernard T. Lee, MD, MBA, MPH, of Beth Israel Deaconess Medical Center and Harvard Medical School, challenges the assumption that antibiotic use is universally protective against post-surgical complications.
In a rigorous, propensity-score-matched analysis, the researchers compared two distinct cohorts of 1,383 patients each. One group had been exposed to antibiotics in the month leading up to their reconstruction, while the control group had not. To ensure the accuracy of the findings, the researchers meticulously matched the groups based on known risk factors for infection, such as obesity, smoking status, and the stage of the underlying breast cancer.
The results were stark: patients in the "exposed" group were 3.91 times more likely to develop an SSI within the first 30 days post-operation. Beyond infection rates, these patients were also twice as likely to suffer from wound-healing complications, such as dehiscence (the separation of wound edges), and were significantly more likely to require the surgical removal of the tissue expander itself.
The Mechanics of Infection: Understanding Dysbiosis
To understand why a medication designed to kill bacteria might lead to a higher rate of infection, one must look at the body’s microbiome. The human body is home to a complex, delicate ecosystem of microorganisms that protect the skin and internal systems from pathogenic invaders.
When a patient takes antibiotics, the drug does not always distinguish between harmful, infection-causing bacteria and the "good" bacteria that form our natural defensive barrier. This disruption is known as "dysbiosis."
"In our study, patients who took antibiotics within 30 days before surgery to place tissue expanders had a four-fold increase in SSI risk—possibly due to disruption of the normal balance of protective versus pathogenic bacteria," Dr. Lee explained.
By clearing out the healthy bacterial flora, antibiotics may inadvertently create a vacuum. This environment can allow opportunistic, infection-causing bacteria to proliferate unchecked, or it may facilitate the development of antibiotic-resistant strains that are significantly harder to treat once they colonize a surgical site. This phenomenon has been observed in other surgical fields, but this study marks the first time it has been specifically linked to the high-stakes environment of tissue expander-based breast reconstruction.
Chronology of the Research and Methodology
The investigation was structured to provide a high level of clinical evidence through a retrospective database analysis.
- Initial Identification: Dr. Lee and his team utilized a large-scale research database to identify patients who had undergone breast reconstruction using tissue expanders.
- Cohort Formation: Two groups of 1,383 patients were identified, separated by their recent antibiotic history (within 30 days of surgery).
- Data Matching: Researchers employed propensity score matching to account for confounding variables. This ensured that the comparison was not skewed by other factors, such as the patient’s BMI, diabetes status, or chemotherapy history.
- The 30-Day Benchmark: The primary endpoint was the incidence of SSI within the first 30 days following the procedure.
- Longitudinal Tracking: The researchers extended their follow-up to 60 and 90 days. While the elevated risks gradually began to subside as the body’s microbiome presumably restored its natural balance, the dangers remained statistically significant throughout the three-month window.
Supporting Data and Clinical Implications
The implications of this study are profound for the field of plastic and reconstructive surgery. Historically, clinicians have relied on preoperative antibiotics as a prophylactic measure to prevent infection. This study does not suggest abandoning antibiotics altogether; rather, it calls for a more nuanced, "surgical stewardship" approach to how and when these drugs are prescribed.
The data suggests that the physiological "echo" of antibiotic use is much longer than previously realized. Even if a patient finishes a course of antibiotics two weeks before surgery, the microbiome may remain in a state of flux, leaving the patient vulnerable to colonization by dangerous pathogens at the surgical site.
Furthermore, the study noted that patients who had been on antibiotics were also more likely to be prescribed antibiotics after their surgery. This creates a potentially vicious cycle: a patient takes antibiotics for a minor ailment, undergoes surgery, develops an infection due to the altered microbiome, and is subsequently prescribed more antibiotics, which may further impede the body’s ability to heal the wound properly.
Official Responses and Expert Perspective
The medical community has responded with cautious interest to the findings. Dr. Lee and his co-authors were careful to note the limitations of their study, specifically the lack of data regarding why the patients were prescribed antibiotics in the first place. Was it a respiratory infection? A urinary tract infection? Or a dental issue? The specific class of antibiotic could also play a role, as different drugs affect the microbiome with varying degrees of severity.
"For plastic surgeons, the findings suggest the need for careful assessment of antibiotic use in patients undergoing tissue expander-based breast reconstruction," Dr. Lee stated.
The authors emphasized that these findings should not result in immediate, drastic changes to clinical practice without further verification. However, they do advocate for a shift in perspective. Surgeons should treat "recent antibiotic use" as a legitimate, measurable risk factor for surgical site infection, just as they would consider smoking or high blood pressure.
Looking Forward: Future Research and Preventative Strategies
The study concludes with a call to action for the broader medical community. The authors strongly recommend that randomized clinical trials be conducted to confirm this link. If the correlation between antibiotic-induced dysbiosis and surgical site infection is definitively proven, it could fundamentally change the pre-surgical consultation process for breast cancer patients.
Potential avenues for future study include:
- Microbiome Mapping: Researching exactly which types of bacteria are lost during antibiotic use and how they specifically relate to post-operative infection in breast reconstruction.
- Probiotic Interventions: Exploring whether the administration of probiotics—or other restorative treatments—could help "reseed" the healthy microbiome in patients who must take antibiotics before surgery, thereby mitigating the risk.
- Refined Prescribing Guidelines: Developing evidence-based guidelines for when it is safe to proceed with reconstruction after a course of antibiotics and whether a "washout period" should be mandated for elective procedures.
Conclusion: A New Standard of Care?
Breast reconstruction is a vital step in the physical and emotional healing of breast cancer survivors. By identifying the hidden risks associated with preoperative antibiotic use, the medical community moves one step closer to making these procedures safer and more predictable.
As we continue to learn more about the human microbiome, it becomes increasingly clear that our internal health is inextricably linked to our surgical outcomes. For now, the takeaway for surgeons and patients alike is clear: the history of medication use in the weeks leading up to surgery is not just a footnote—it is a critical piece of the patient’s clinical profile. As research progresses, the goal remains the same: minimizing the risk of infection and ensuring that every patient has the best possible foundation for a successful recovery.
For more information on the study, "Recent Antibiotic Use and Surgical Site Infections in Tissue Expander–Based Breast Reconstruction: A Propensity Score–Matched Analysis," readers can access the full report in the February issue of Plastic and Reconstructive Surgery®.
About the Author
